title: Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions.
abstract: OBJECTIVE
  This observational study evaluated the clinical and angiographic outcomes of patients with aorto-ostial coronary artery disease treated with sirolimus-eluting stents (SESs) or with bare metal stents (BMSs).
  
  
  BACKGROUND
  The safety and effectiveness of SESs for the treatment of aorto-ostial lesions have not been demonstrated.
  
  
  METHODS
  We identified 82 consecutive patients who underwent percutaneous coronary interventions in 82 aorto-ostial lesions using the SES (32 patients) or BMS (50 patients) and compared the two groups of patients. The incidence of major adverse cardiac events (MACE), including death or Q-wave myocardial infarction (MI), target lesion revascularization (TLR), and target vessel revascularization (TVR), were recorded in-hospital and at a 10-month follow-up.
  
  
  RESULTS
  All stents were implanted successfully. There were no statistically significant differences regarding major in-hospital complications between the two groups. At 10-month follow-up, two (6.3%) patients in the SES group and 14 (28%) patients in the BMS group underwent TLR (p = 0.01); MACE were less frequent in the SES group compared to the BMS group (19% vs. 44%, p = 0.02). Angiographic follow-up showed lower binary restenosis rates (11% vs. 51%, p = 0.001) and smaller late loss (0.21 +/- 0.31 mm vs. 2.06 +/- 1.37 mm, p < 0.0001) in the SES group.
  
  
  CONCLUSIONS
  The main finding of our study is that, compared to the BMS, implantation of the SES in aorto-ostial lesions appears safe and effective, with no increase in major in-hospital complications and a significant improvement in restenosis and late event rates at 10-month follow-up.
authors.affiliation: Centro Cuore Columbus, Milan, Italy.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Iakovou
authors.forename: Lei
authors.initials: L
authors.lastname: Ge
authors.forename: Iassen
authors.initials: I
authors.lastname: Michev
authors.forename: Giuseppe M
authors.initials: GM
authors.lastname: Sangiorgi
authors.forename: Matteo
authors.initials: M
authors.lastname: Montorfano
authors.forename: Flavio
authors.initials: F
authors.lastname: Airoldi
authors.forename: Alaide
authors.initials: A
authors.lastname: Chieffo
authors.forename: Goran
authors.initials: G
authors.lastname: Stankovic
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Vitrella
authors.forename: Mauro
authors.initials: M
authors.lastname: Carlino
authors.forename: Nicola
authors.initials: N
authors.lastname: Corvaja
authors.forename: Carlo
authors.initials: C
authors.lastname: Briguori
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000628:therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus